5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development
PCS6422
November 1, 2000
Grem JL.
View PublicationA multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer
PCS6422
April 1, 2000
Schilsky RL, Bukowski R, Burris H 3rd, Hochster H, O'Rourke M, Wall JG, Mani S, Bonny T, Levin J, Hohneker J.
View PublicationPhase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil
PCS6422
February 1, 2000
Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor SP, Sartorius SE, Donehower RC, Grochow LB, Spector T, Hohneker JA, Rowinsky EK.
View PublicationIndividualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits
PCS6422
August 1, 1996
Milano G, Etienne MC.
View PublicationRelationship between fluorouracil systemic exposure and tumor response and patient survival.
PCS6422
June 1, 1994
Milano G, Etienne MC, Renée N, Thyss A, Schneider M, Ramaioli A, Demard F.
View Publication5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil
PCS6422
December 1, 1993
Baccanari DP, Davis ST, Knick VC, Spector T.
View PublicationDihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
PCS6422
November 15, 1993
Lu Z, Zhang R, Diasio RB.
View PublicationContinuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer
PCS6422
October 1, 1989
Chang AY, Most C, Pandya KJ.
View PublicationContinuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients
PCS6422
March 1, 1989
Hansen R, Quebbeman E, Ausman R, Frick J, Ritch P, Schulte W, Haas C, Beatty P, Anderson T.
View Publication